The counter had a total traded volume of 01:19PM shares so far with a turnover of Rs 6.36 crore on BSE. The stock traded at a price-to-earnings multiple of 7.39 and a price-to-book ratio of 2.36.
A higher P/E ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.
The price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry.
Promotor/FII Holding
Promoters held 51.83 per cent stake in the company as of 30-Sep-2021, while FIIs and domestic institutional investors ownership stood at 23.41 per cent and 13.82 per cent, respectively.
Key Financials
The company reported consolidated net sales of Rs 6038.5 crore for the quarter ended 30-Sep-2021, up 4.41 per cent from the previous quarter’s Rs 5783.29 crore and up 7.63 per cent from the year-ago quarter’s Rs 6537.19 crore.
Its profit for the latest quarter stood at Rs 696.99 crore, down 13.55 per cent from the same quarter a year ago.
